Results 91 to 100 of about 4,135 (231)
Abstract Background Higher muscle strength is associated with improved overall health and lower mortality. Muscle strength changes during gender‐affirming hormone therapy is possibly linked to gender‐affirming hormone therapy modality, age at initiation, gender‐affirming hormone therapy duration, and physical activity.
Mathilde Kamp Nørlund+7 more
wiley +1 more source
Vitamin D levels and biomarkers of male fecundity: A study from the Danish National Birth Cohort
Abstract Background Vitamin D is metabolised throughout the male reproductive system, suggesting a direct regulatory role of vitamin D in male reproduction. Objectives To investigate the association between plasma vitamin D levels at sperm ejaculation and during spermatogenesis and biomarkers of male fecundity in young men.
Anne Gaml‐Sørensen+8 more
wiley +1 more source
Abstract Introduction Testosterone therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. However, concerns about its cardiovascular safety have historically tempered its use.
Michael Zitzmann+15 more
wiley +1 more source
Abstract Background There is growing interest in the relationship between sleep disorders and erectile dysfunction. We present the results from a 2015 follow‐up study in relation to the 2007 edition of Epidemiologic Sleep Study (EPISONO), a population‐based sleep study conducted in São Paulo, Brazil, and from the 4th edition of EPISONO (2018), with ...
Monica Levy Andersen+4 more
wiley +1 more source
Systematic review of PSA reference intervals in the gender diverse population with prostates
Objectives To determine mean/median serum total prostate‐specific antigen (PSA) levels in transgender women and non‐binary people with prostates (TWNBPP) who have received gender‐affirming hormone therapy (GAHT) or an orchidectomy. The secondary objective was to identify other quantitative information that influences PSA levels in this population ...
Rose Hall+4 more
wiley +1 more source
Preferences between three options for androgen deprivation therapy: a focus group study
Objectives Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone‐releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists.
Hannah L. Rush+13 more
wiley +1 more source
Individual variation in animal communication: from species averages to unique voices
ABSTRACT The comparative study of communicative behaviour in non‐human animals, especially primates, has yielded crucial insights into the evolution of human language. This research, mostly focused on the species and population level, has improved our understanding of the various socio‐ecological factors that shape communication systems.
Angèle Lombrey, Marlen Fröhlich
wiley +1 more source
This study develops a metastasis‐associated prognostic risk score (MAPRS), based on multicenter transcriptome data and machine learning algorithms, and validates it using histopathological samples. MAPRS effectively predicts recurrence‐free survival (RFS) and progression‐free survival (PFS) in prostate cancer patients, particularly when combined with ...
Jianpeng Zhang+11 more
wiley +1 more source
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley +1 more source
Serum Estradiol Concentrations With Estradiol 0.06% Gel in Transgender and Gender‐Diverse Adults
ABSTRACT Objective Transgender and gender‐diverse individuals undergoing estradiol therapy for gender affirmation are typically treated with oral or transdermal estradiol, with transdermal estradiol recommended for those aged > 45 years. There are limited data evaluating estradiol gel in gender‐affirming hormone therapy regimens. We aimed to assess the
Raquel A. Maggacis+2 more
wiley +1 more source